While Johnson & Johnson has underperformed by -0.25%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, JNJ fell by -3.36%, with highs and lows ranging from $168.85 to $143.13, whereas the simple moving average fell by -4.05% in the last 200 days.
On December 10, 2024, BofA Securities started tracking Johnson & Johnson (NYSE: JNJ) recommending Neutral. A report published by Wolfe Research on November 15, 2024, Initiated its previous ‘Outperform’ rating for JNJ. Daiwa Securities also Downgraded JNJ shares as ‘Neutral’, setting a target price of $150 on the company’s shares in a report dated July 23, 2024. Goldman Initiated an Neutral rating on May 30, 2024, and assigned a price target of $160. HSBC Securities April 18, 2024d its ‘Hold’ rating to ‘Buy’ for JNJ, as published in its report on April 18, 2024. Wells Fargo’s report from December 13, 2023 suggests a price prediction of $163 for JNJ shares, giving the stock a ‘Equal Weight’ rating. UBS also rated the stock as ‘Buy’.
Analysis of Johnson & Johnson (JNJ)
Investors in Johnson & Johnson will get a return regardless of how the company performs over the next quarter since the company’s dividend stands at $4.91 per share. Further, the quarter-over-quarter increase in sales is 5.27%, showing a positive trend in the upcoming months.
One of the most important indicators of Johnson & Johnson’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 20.89% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.79, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and JNJ is recording 6.65M average volume. On a monthly basis, the volatility of the stock is set at 1.48%, whereas on a weekly basis, it is put at 1.33%, with a loss of -2.05% over the past seven days. Furthermore, long-term investors anticipate a median target price of $176.74, showing growth from the present price of $149.23, which can serve as yet another indication of whether JNJ is worth investing in or should be passed over.
How Do You Analyze Johnson & Johnson Shares?
The Drug Manufacturers – General market is dominated by Johnson & Johnson (JNJ) based in the USA. When comparing Johnson & Johnson shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 24.67, there is a growth in quarterly earnings of -43.91%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.12%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 72.74% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
JNJ shares are owned by institutional investors to the tune of 72.74% at present.
